RecruitingPhase 1NCT07600476

A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors

Sponsor

Kupando GmbH

Enrollment

21 participants

Start Date

Apr 1, 2026

Study Type

INTERVENTIONAL

Conditions

Cutaneous Melanoma Merkel Cell Carcinoma of Skin Basal Cell Carcinoma of Skin Cutaneous Squamous Cell Carcinoma (CSCC)Mucosal Melanoma

Summary

The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called KUP-101A for people with basal cell carcinoma of skin, cutaneous melanoma, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.